$CELG News

Last published 6y ago

6y agoAZN-GB GILD MRK PFE+5AstraZeneca contacted Gilead over potential megamergerCNBCBritain's AstraZeneca has approached U.S. rival Gilead Sciences about a possible merger to form one the world's largest drug companies.
6y agoCELG TEVA CNTX GNMX+1NexImmune Appoints Sol Barer as Chairman of the Board of DirectorsGlobeNewswireGAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation...
6y agoBMY CELGBristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the final results of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bristol-Myers Squibb No ...
6y agoAMGN CELG BMYAmgen Completes Acquisition Of Otezla® (apremilast)PR NewswireAmgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral,...
6y agoCELG BMY CELGZCelgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers SquibbBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights (NASDAQ: CELGZ) (“Celgene CVRs”) that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the N ...
6y agoBMY CELG AMGNBristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma CompanyBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
6y agoBMY CELGBristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today that it currently expects there will be no further extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be is ...
6y agoBMY CELG AMGNBristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene AcquisitionBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with the pending merger of Bristol-Myers Squibb and Celgene Corporation (NASDAQ:CELG), thereby permitting the parties to close the transaction. As announced on August 26, 2019, Celgene entered into an agreement with Am ...
6y agoCELGCelgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular LymphomaBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of REVLIMID® (lenalidomide) in combination with rituximab (anti-CD20 antibody) (R²) for the treatment of adult patients with previously treated follicular lymphoma ...
6y agoBMY CELGBristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bris ...
7y agoEDIT CELGEditas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune DiseasesGlobeNewswireThe companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells Editas Medicine to receive a $70 million payment and may be eligible for...
7y agoBMY CELGBristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bris ...
7y agoCELG XLRNFDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell TransfusionsBusiness WireSUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved REBLOZYL® (luspatercept-aamt) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.1 REBLOZYL is not indicated for use as a substitu ...
7y agoCNST NNVC AGEN GSK+1Global Nanotechnology and Nanomedicine Treatment Markets Could Reach $350 Billion by 2025PR NewswireResearchers in nanomedicine are making some big-time advances according to reports in various industry journals. Nanomedicine, a relatively new but...
7y agoBMY CELGBristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bris ...
7y agoAZN CELGAntengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364PR NewswireAntengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (LSE/STO/NYSE: AZN) under which Antengene has...
7y agoCELGCelgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual MeetingBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced data from nearly 70 Company-sponsored, global alliance and investigator-initiated clinical studies evaluating Celgene’s investigational and approved therapies will be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, December 7-10, in Orlando, Fla.
7y agoGILD CELG MRK PFEBiotechs Target Innovative Advances in the Battle Against CancerPR NewswireCancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World...
7y agoBMY CELGBristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bris ...
7y agoBMY CELGBristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bris ...
7y agoCELGCelgene Reports Third Quarter 2019 Operating and Financial ResultsBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) reported third quarter 2019 total revenue of $4,520 million, a 16 percent increase compared to $3,892 million in the third quarter of 2018.
7y agoBMY CELGBristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bris ...
7y agoBMY CELGBristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation NotesBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the “Bris ...
7y agoINMB CELG MRK GILD+1Companies Seek an Innovative Solution to the Growing Cancer RatesPR NewswireCancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World...
7y agoCELGCelgene Corporation Names Second Round of Celgene Cancer Care Links™ Program Grant RecipientsBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the world. The program and initial grants were announced in December 2018.
7y agoCELGCelgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary EndpointsBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response ( ...
7y agoCELGData from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple SclerosisBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms of multiple sclerosis (RMS), at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, September 11-13, 201 ...
7y agoCELGU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With MyelofibrosisBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1
7y agoCELGCelgene Reports Second Quarter 2019 Operating and Financial ResultsBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 million in the second quarter of 2018.
7y agoCELGCelgene and the Multiple Sclerosis Association of America Bring MS MindShift Initiative and “Brain Bulb” Hot Air Balloon to Festival to Raise Awareness of Multiple Sclerosis and Brain HealthBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) are bringing the MS MindShift: A New View of MS initiative to the 37th Annual QuickChek New Jersey Festival of Ballooning in Readington, NJ, on July 26-28, where the MS MindShift “Brain Bulb” hot air balloon will fly to raise awareness of multiple sclerosis (MS) and brain heal ...
7y agoCELGFDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s DiseaseBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ...
7y agoCELGUS FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple SclerosisBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with relapsing forms of multiple sclerosis (RMS) in the United States. The European Medicines Agency (EMA) also accepted for review the Marketing Authorization Application for ozan ...
7y agoCELGCelgene Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019Business WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that data from the TRANSCEND CLL 004 and TRANSCEND NHL 001 trials studying the investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel; JCAR017) in patients with B-cell blood cancers were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting i ...
7y agoCELG XLRNCelgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-ThalassemiaBusiness WireSUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplasti ...
7y agoCELGCelgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with RuxolitinibBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib in patients with myelofibrosis previously treated with ruxolitinib. This updated analysis of fedratinib employed intent-to-treat (ITT) principles and utilized a narrower de ...
7y agoCELGCelgene and the Multiple Sclerosis Association of America Team Up to Launch MS MindShift for Awareness of Multiple Sclerosis and Brain HealthBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) today announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that provides new perspective on multiple sclerosis (MS). The campaign aims to educate about the critical role the brain plays in the disease and what people living with MS can ...
7y agoCELGCelgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple SclerosisBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtyp ...
7y agoBMY CELGBristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor MaterialsBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company’s (NYSE:BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG). In addition to its March 19 investor presentation, the Company today also made available on Bristol-Myers Squibb’s website at www.bestofbiopharma.com and ...
7y agoBMY CELGBristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with CelgeneBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (NASDAQ: CELG).
7y agoCELGCelgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic CancerBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced two updates for ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer.
7y agoCELGCelgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple SclerosisBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S ...
7y agoBMY CELGBristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with CelgeneBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today filed an investor presentation with the Securities and Exchange Commission (SEC), and the Board of Directors sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG). The investor presentation is available on www.bestofbiopharma.com ...
7y agoCELGU.S. FDA Grants Priority Review for Fedratinib New Drug Application in MyelofibrosisBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority Review. Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis, a serious bone marrow disorder that disrupts the body’s normal produ ...
7y agoBMY CELGBristol-Myers Squibb Issues Statement in Response to Starboard’s LetterBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement in response to a letter from Starboard Value (“Starboard”):
7y agoCELGCelgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-ThalassemiaBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the company’s supplemental New Drug Application (sNDA) for REVLIMID® (lenalidomide) in combination with rituximab (R²) for the treatment of patients with previously treated follicular and marginal zone lymphoma. Under the Pres ...
7y agoBMY CELGBristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with CelgeneBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Celgene Corporation (NASDAQ:CELG). Bristol-Myers Squibb will commence mailing the joint proxy statement / prospectus to its stockholders on or about February 22.
7y agoBMY CELGBristol-Myers Squibb Provides Update on Pending Transaction with CelgeneBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today provided an update on its proposed acquisition of Celgene Corporation (NASDAQ:CELG).
7y agoCELGCelgene Corporation (CELG) CEO Mark Alles on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
7y agoCELGCelgene Reports Fourth Quarter and Full Year 2018 Operating and Financial ResultsBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2018. For the fourth quarter of 2018, net product sales were $4,036 million, an increase of 16 percent year-over-year. Fourth quarter total revenue increased 16 percent year-over-year to $4,037 million.
7y agoCELGCelgene Corporation Announces 2019 Financial Guidance and Key MilestonesBusiness WireSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today provides a business update, including confirmation that the company achieved its guidance for full-year 2018; its financial guidance for 2019; and reaffirmation of its expected 2020 financial targets.